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Abstract 
Objective. To identify country-level correlates of geographi-
cal variations in cervical cancer (CC) mortality in Latin Amer-
ica and the Caribbean (LAC). Materials and methods. CC 
mortality rates for LAC countries (n=26) were examined 
in relation to country-specific socio-economic indicators 
(n=58) and Human Papilloma Virus (HPV) prevalence using 
linear regression models. Results. High mortality at ages 
<5 years, low per capita total expenditure on health, and 
low proportion of the population with access to sanitation 
were identified as the best independent predictors of CC 
mortality (R2=77%). In the subset of countries (n=10) with 
HPV prevalence estimates, these socio-economic indicators 
together with high-risk HPV prevalence explained almost all 
the between-country variability in CC mortality (R2=98%). 
Conclusion. The findings suggest that continuing socio-
economic improvements in LAC countries will be associated 
with further reductions in CC mortality even in the absence 
of organised population-based screening and vaccination 
programmes.
Keywords: uterine cervical neoplasms; papillomaviridae; mass 
screening; Latin America
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Determinantes a nivel país de la mortalidad por cáncer
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Resumen
Objetivo. Identificar variables a nivel de país que expliquen 
las variaciones geográficas en la mortalidad por cáncer 
cervicouterino (CaCu) en América Latina y el Caribe (AL). 
Materiales y métodos. Se examinaron las tasas de mor-
talidad por CaCu de cada país (n=26) mediante modelos de 
regresión lineal en relación con indicadores socioeconómicos 
(n=58) y prevalencia del virus del papiloma humano (VPH). 
Resultados. Alta mortalidad en menores de cinco años, 
bajo gasto total en salud per-cápita y baja proporción de 
población con acceso a saneamiento básico son los mejores 
predictores de mortalidad por CaCu (R2=77%). En los paí-
ses (n=10) con estimaciones de prevalencia de VPH, estos 
indicadores socioeconómicos y la prevalencia de VPH de 
alto riesgo explicaron el 98% de la variabilidad de CaCu en 
AL. Conclusión. Las mejoras en el nivel socioeconómico 
en AL están asociadas con reducciones en la mortalidad por 
CaCu, a pesar de la ausencia de programas organizados de 
tamizaje e inmunización contra VPH.
Palabras clave: neoplasias del cuello uterino; papillomaviridae 
humano; tamizaje masivo; América Latina
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Cervical cancer (CC) is the second most common female non-skin cancer in the world. According 
to Globocan 2008,1 13% of all CC cases and 11% of 
all CC deaths worldwide occur in Latin America and 
the Caribbean (LAC), with rates being higher than in 
more developed countries. There is, however, marked 
between-country variability in CC rates in LAC with a 
four to five-fold difference in rates between high (e.g. 
Nicaragua and Guyana) and low risk countries (e.g. 
Uruguay and Chile).1,2 Persistent infection with high-
risk Human Papillomavirus (HPV) is a necessary cause 
for CC development,3 but geographical variations in 
the prevalence of HPV do not seem to fully explain the 
variability in CC rates worldwide.4 Organised cervical 
screening programmes based on cytology can reduce 
CC incidence and mortality rates5 by as much as 80-
90%.6 Both ecological and individual-based studies have 
shown that markers of socio-economic (SE) status, such 
as educational level, are related to CC incidence and 
mortality, with women with low SE status being at high-
er risk of developing, or dying from, this cancer.7,8
We conducted an ecological study to assess the extent 
to which between-country differences in CC mortality 
in LAC are accounted by level of SE development, HPV 
prevalence and screening activity.
Materials and methods
CC mortality rates
Country-specific CC mortality rates (age-adjusted to 
the World standard population) for 2008 were extracted 
from GLOBOCAN 2008.1 These rates were estimated 
from death certification data provided by each country 
to the World Health Organization (WHO) except for 
Bolivia, Guyana, Honduras, Jamaica and Haiti. For 
these countries, CC mortality estimates were corrected 
for under-reporting (Guyana), or derived using data 
on CC incidence rates and survival (Bolivia) or CC 
mortality from neighbouring countries (Honduras, 
Jamaica).1 Haiti was excluded from the analysis because 
its GLOBOCAN estimates were markedly different for 
2002 and 2008 (i.e. age-adjusted rates of 48 and 10 per 
100 000 women, respectively).1,9
Level of SE development
Data on demographic, SE and public health indica-
tors for the years 2000-2005 were extracted, for each 
LAC country, from official web pages or reports pub-
lished by non-governmental organisations, including 
the WHO,10 the Pan-American Health Organisation 
(PAHO),11-13 the United Nations Statistics Division14 
and Human Development Report.15 These indicators 
were categorised into nine strata (table I): demographic 
(eight indicators), mortality (eight), morbidity (two), 
immunisation coverage (five), tobacco use (two), sexual 
and reproductive behaviour (six), health services (ten), 
economic (eleven) and development (six) indicators. 
Linear univariate regression models, weighted by size 
of the female population in each country, were fitted 
to examine the association between each one of these 
58 indicators and CC mortality at a country level. For 
each one of the nine strata described above, the indica-
tor with the highest R2, a p-value<0.05 and available 
data for all LAC countries examined was chosen to be 
included in a multiple regression model. The tobacco 
use stratum was excluded because none of its indicators 
had information for all the countries examined (table I). 
The correlation between the remaining eight selected 
stratum-specific indicators was then evaluated and 
whenever two of these were strongly correlated (r>0.80), 
the one with the larger p-value and/or smaller R2 was 
replaced by the next indicator in the same stratum that 
most closely fulfilled the above criteria. This process 
was repeated until none of the eight stratum-specific 
indicators were strongly correlated with each other 
(r<0.80). A multiple linear regression model was then 
fitted to the final selection of stratum-specific indicators, 
and the log-likelihood ratio test used to identify the best 
independent predictors of CC mortality.
 A composite risk score was generated on the basis 
of the identified predictors. Firstly, the 26 LAC countries 
were ranked separately according to the values of each 
one of the identified predictors and a predictor-specific 
risk score assigned to each country to reflect this rank-
ing (e.g. for a predictor positively associated with CC 
mortality a score of 1 was assigned to the country with 
the lowest predictor value and a score of 26 to the 
country with the highest; for a predictor inversely as-
sociated with CC mortality a score of 1 was assigned to 
the country with the highest predictor value and a score 
of 26 to the country with the lowest). A composite risk 
score for each country was then calculated as the sum 
of its predictor-specific risk scores (i.e. for 3 predictors, 
country-specific composite scores could range from 3 to 
78 depending on the direction of their association with 
CC mortality).
HPV prevalence
Data on country-specific HPV prevalence estimates, any 
genotype and high-risk genotypes (HPV16 and HPV18), 
and the women’s ages at the time of HPV assessment, 
were extracted from the WHO/ICO Information Centre 
on HPV and CC.16 Its website presents worldwide data 
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Table I
Country-level demographiC, soCioeConomiC and publiC health Correlates, in 2000-2005, of CerviCal CanCer 
mortality in latin ameriCa and the Caribbean islands (laC)
Type of Indicator  Percentil ß R2 P
Indicator (no. of countries for which data were available) / [reference] 50% Interquantil Range
    25%-75%   
Demographical characteristics            
 Urban population (%) (26)/11 63.60 57.80- 77.40 -0.18 0.4 0.001
 Proportion of population aged less than 15 years (%) (26)/11 28.94 25.90- 31.61 0.57 0.47 <0.001
 Proportion of population aged 60 years and over (%) (26)/11 8.04 6.71- 10.20 -0.83 0.37 0.001
 Dependency ratio [Dependent population per 100 productive population] (26)/11 57.55 52.70- 64.80 0.22 0.34 0.002
 Annual rate of population growth (%) (26)/11 1.40 0.70- 1.70 5.41 0.41 <0.001
 Crude birth rate (per 1 000 population) (26)/11 20.75 18.30- 23.90 0.64 0.54 <0.001
 % of the population of Native origin (26)/10 4.00 2.00- 14.00 0.08 0.22 0.015
 % of the population of Afro American origin (15)(a)/10 9.00 2.00- 21.00 -0.02 0.03 0.53 
Public health indicators        
 Mortality           
  Female life expectancy at birth (in years) (26)/10 74.00 71.00- 78.00 -0.75 0.48 <0.001
  Female healthy life expectancy at birth (in years) (26)/10 64.20 62.20- 68.00 -0.6 0.38 0.001
  Infant mortality rate (per 1 000) (26)/10 22.00 16.00- 31.00 0.14 0.16 0.046
  Neonatal mortality rate (per 1 000) (26)/10 15.00 10.00- 18.00 0.52 0.35 0.001
  Maternal mortality ratio (per 100 000) (26)/10 120 78.00-170.00 0.01 0.23 0.013
  Age-standardized cancer (all sites combined)mortality rate (per 100 000) (26)/10 130.30 112.20- 141.80 0.03 0.06 0.217
  Percentage of years of life lost to non-communicable diseases (%) (26)/10 44.55 36.50-56.80 -0.2 0.43 <0.001
  Estimated mortality under 5 years of age (per 1 000) (26)/10 28.80 16.70-43.60 0.2 0.57 <0.001
 Morbidity        
  Crude annual incidence of tuberculosis (100 000 population) (26)/10 66.85 32.80- 106.80 0.04 0.38 <0.001
  Prevalence of low birth weight [%] (26)/10 9.50 7.00- 12.00 0.81 0.32 0.003
 Immunization Coverage       
  Proportion of one-year-olds immunized with one dose of measles (%) (26)/10 92.00 86.00- 95.00 -0.23 0.31 0.003
  Proportion of one-year-olds immunized with three doses of diphtheria
  tetanus toxoid and pertussis (DTP3) (%) (26)/10 90.00 85.00- 94.00 -0.29 0.31 0.003
  Proportion of one-year-olds immunized with three doses of Hepatitis B (HepB3) (%) (23)(b)/10 89.00 83.00- 94.00 -0.29 0.32 0.003
  Proportion of under-one-year population immunized against poliomyelitis (%) (26)/11 91.50 88.00- 95.00 -0.27 0.3 0.004
  Proportion of under-one-year population immunized against tuberculosis (%) (22)(c) /11 96.00 92.00- 99.00 -0.49 0.31 0.007
 Tobacco Use
  Prevalence of current tobacco smoking among adult women (%) (9)(d)/10 13.20 7.00- 17.50 -0.28 0.61 0.012
  Prevalence of tobacco smoking among adolescents aged 12-18 years (%) (25)(e)/11 20.50 18.30- 25.40 -0.31 0.25 0.01
Sexual and reproductive behaviour
 Total fertility rate (26)/11 2.50 2.20- 2.80 4.69 0.49 <0.001
 Specific fertility rate in women aged 15-19 years (per 1 000 population) (26)/11 74.60 58.50- 85.20 0.08 0.14 0.055
 Percentage of women who gave birth between 15-19 years (26)/13 7.00 5.00- 9.00 0.58 0.09 0.094
 Prevalence of use of any contraceptive methods among women (%) (26)/11 59.40 46.30- 69.00 -0.04 0.04 0.315
 Use of oral contraceptives among women (21)(f) /12 11.80 7.10- 20.70 -0.47 0.37 0.003
 Age of first intercourse among women (11)(g)/12 19.00 18.55- 19.20 -1.04 0.17 0.186
(Continue…)
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Health services indicators
 Number of physicians (per 1 000 population) (25)(h)/10 1.21 1.05- 1.50 -1.37 0.17 0.04
 Number of nurses (per 1 000 population)(25) (i)/10 1.57 0.90- 2.87 0.1 0 0.797
 Number of outpatient care facilities  (26)/11 1818.0 367.00- 5835.0 -0.001 0.11 0.106
 Hospital beds ratio (per 1 000 population) (26)/111 1.60 1.00- 2.90 -1.31 0.22 0.016
 Outpatient health care visits ratio (per 1 000 population) (25)(j)/11 1774.3 1070.70- 2502.3 -0.001 0.07 0.188
 Hospital discharges ratio (per 1 000 population) (26)/11 63.45 54.20- 80.00 -0.03 0.07 0.202
 Proportion of pregnant women followed by trained personnel during pregnancy (%) (26)/11 88.10 79.00- 94.00 -0.02 0.02 0.443
 Proportion of deliveries attended by trained personnel (%) (26)/11 94.25 83.70- 99.10 -0.16 0.41 <0.001
 Coverage of death registrations (%) (22)(k) /10 87.05 73.80- 97.00 -0.13 0.43 0.001
 Proportion of certified deaths due to ill-defined and unknown conditions (%)(25)(h)/11 6.40 2.40- 12.50 0.15 0.14 0.06
Economic statistics
 Total expenditure on health as percentage of  GDP (26)/10 6.95 5.30- 7.60 -1.1 0.2 0.022
 General government expenditure on health as a percentage of total expenditure on health (26)/10 48.35 44.30- 64.00 -0.04 0.02 0.449
 Per capita total expenditure on health at USD (international dollar rate) (26)/10 322.00 233.00- 597.00 -0.01 0.64 <0.001
 Per capita government expenditure on health at USD (international dollar rate) 187.50 109.00- 345.00 -0.02 0.61 <0.001
 GDP per capita, PPP  (24)(l) /10 6779.2 4018.7- 9109.5 -0.001 0.76 <0.001
 Annual GDP growth rate (%) (25)(m) /11 2.50 1.30- 3.90 -0.25 0.09 0.157
 Increase of GDP per capita PPP in the last 10 years(24)(l) /11 11.48 6.61- 22.79 -0.12 0.14 0.075
 Highest 20%/Lowest 20% income ratio  (22)(n) /11 18.00 11.00- 21.50 -0.11 0.03 0.439
 Proportion of the population living below the poverty line (living with less than $1 a day) (21)(o)/11 8.20 3.00- 16.40 0.39 0.62 <0.001
 Proportion of the population below the national poverty line (%) (23)(p)/11 35.00 21.80- 49.00 0.09 0.21 0.058
 Proportion of the labour force who are currently unemployed (%)  (26)/11 9.85 6.40- 14.00 -0.05 0.01 0.665
Development
 Proportion of the population with sustainable access to an improved water 
 source (%) (26)/11 91.00 85.00- 94.00 -0.59 0.54 <0.001
 Proportion of the population with access to improved sanitation (%) (26)/11 76.00 66.00- 92.00 -0.25 0.57 <0.001
 Female literacy rate (%) (26)/13 92.50 87.20- 96.60 -0.32 0.42 <0.001
 Average number of years of formal education for the total population (25)(q)/14 13.00 12.00- 14.00 -1.03 0.16 0.048
 Average number of years of formal education for the female population (22)(r) /14 13.00 12.00 14.00 -1.16 0.27 0.014
 Human Development Index*, 2004  (26)/15 0.78 0.73- 0.83 -64.38 0.77 <0.001
GDP: Growth Domestic Product, PPP: Purchasing power parity      
* Human Development Index: is a composite statistic used to rank countries by level of “human development” which takes into account life expectancy, 
literacy, level of education and standards of living
(a) excluded: Argentina, Bahamas, Barbados, Belize, Chile, El Salvador, Guatemala, Guyana, Jamaica, Suriname, Trinidad and Tobago
(b) excluded: Chile, Guatemala, Suriname      
(c) excluded: Bahamas, Barbados, Suriname & Trinidad & Tobago     
(d) included: Brazil, Chile, Dominican Republic, Ecuador, Guatemala, Honduras, Mexico, Paraguay, Uruguay, 
(e) excluded: Dominican Republic     
(f) excluded: Argentina, Chile, Panama, Uruguay, Venezuela   
(g) excluded: Argentina, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Cuba, Guayana, Mexico, Panama, Suriname, Trinidad and Tobago, Uruguay, Venezuela
(h) excluded: Honduras      
(i) excluded: Venezuela      
(j) excluded: Colombia       
(k) excluded: Bolivia, Honduras, Jamaica, Suriname    
(l)  excluded: Cuba, Suriname      
(m) excluded: Cuba      
(n) excluded: Barbados, Belize, Cuba, Suriname
(o) excluded: Barbados,Belize, Bolivia, Cuba, Suriname
(p) excluded: Mexico, Uruguay, Venezuela, Barbados, Belize, Bolivia, Cuba, Suriname
(q) excluded: Ecuador      
(r) excluded: Bolivia, Costa Rica, Ecuador, Guyana
(Continue)
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on HPV prevalence4,17 compiled through systematic 
reviews of the literature published between 1995 and 
2009; publications were eligible if HPV assessment was 
based on polymerase chain reaction (PCR) or Hybrid 
Capture2 (HC2), and the sample included >90 women 
with normal cytological findings. Age-specific HPV 
prevalence estimates were available from the WHO/
ICO website for 10 LAC countries (Argentina, Brazil, 
Chile, Colombia, Costa Rica, Guatemala, Honduras, 
Mexico, Paraguay and Peru). Regression models, re-
stricted to these 10 countries, were fitted to examine the 
association between HPV prevalence (any and high-risk 
HPV) and CC mortality, adjusting for age at HPV as-
certainment and also additionally for the SE predictors 
identified by the analysis described above.
Cervical screening
Information on screening policies and their level of 
implementation, including Pap smear coverage estimates 
from nationally representative surveys and other sources, 
were extracted from a previously published source18 and 
updated using the same methodology as previously. In-
formation was also gathered on the use of HPV detection 
methods and on HPV vaccination policies.
 Analyses were conducted in Stata v.10. The study 
was carried out at the London School of Hygiene and 
Tropical Medicine. Ethical approval was not required 
because only publicly-available secondary data were 
analysed.
Results
There were marked between-country differences for 
most demographic, SE and public health indicators 
(table I). For instance, there was a 9.5-fold difference 
between the countries with the highest (Bolivia) and the 
lowest (Chile) mortality rate among children aged under 
5 years, and a 7-fold difference between the countries 
with the highest (Bahamas) and the lowest (Bolivia) 
per-capita expenditure on health.
 The univariate analyses showed that countries with 
the highest CC mortality rates tended to be those with the 
youngest age-structure, lowest degree of urbanisation, 
lowest SE development and poorest health indicators 
(table I). Crude birth rate, mortality rate under five years, 
incidence of tuberculosis, proportion of one-year-olds 
immunized with one dose of measles, total fertility rate, 
proportion of deliveries attended by trained personnel, 
per capita total expenditure on health, and proportion of 
the population with access to improved sanitation were 
the variables selected to represent each one of the eight 
strata of indicators in the multiple regression analysis. 
Mortality rate under 5 years of age, per capita total ex-
penditure on health and proportion of the population 
with access to improved sanitation were identified as 
the best independent predictors of CC mortality in LAC 
(table II), accounting for 77% of the between-country 
variability in rates. There was a positive linear associa-
tion between the composite risk score and CC mortality 
at a country level (figure 1).
 Stratifying LAC countries according to their CC 
mortality (table III) showed, as expected, that the high-
est CC mortality-stratum had, on average, the highest 
mortality rate at age under-5-years, the lowest mean 
per capita total expenditure on health, and the lowest 
proportion of the population with access to improved 
sanitation.
 In analyses restricted to the subset of 10 countries 
with available HPV data, the three independent SE pre-
dictors identified above explained 90% of the between-
country variability in CC mortality (table II) whereas 
age-adjusted prevalence of any HPV genotype, or of high-
risk HPV genotypes, alone explained only 8-9% (table II). 
The correlation between HPV and SE predictors was low 
(r<0.30). Nevertheless, the R2 increased to 98% when both 
SE predictors and high-risk HPV prevalence (to 97% if the 
latter was replaced by prevalence of any HPV genotype) 
were included in the same model (table II).
 Cytology-based screening programmes were first 
introduced in LAC in the early 1960s (table IV). Most 
programmes are opportunistic. Only the Chilean na-
tional programme recommends a national call-recall 
system,19 but there is no evidence that such recommen-
dation has been implemented. A few local organised 
screening programmes have been set up (e.g. certain 
regions of Brazil),20-22 but none has established a call-
recall system. Different methodologies and age-groups 
were used to estimate Pap smear coverage, thus mak-
ing between-country comparisons difficult. Estimates 
for Pap-smear coverage within 2-3 years prior to the 
survey (available for nine countries) ranged from 31 to 
69%.20,23-31 Estimates of the proportion of women ever 
screened (available for seven countries) ranged from 35 
to 85%,25,29,32-35 being greater than 80% (at ages 15-49) 
only in El Salvador.33 Those that report annual screen-
ing ranged from 22.7% to 44.8%.35-38 Screening relied 
mainly on cytology (Papanicolaou test), but in recent 
years visual inspection after the application of acetic 
acid (VIA) and HPV testing have also been incorporated 
into national screening policies (e.g. the latter is cur-
rently being used in primary screening in Mexico and 
in demonstration projects in Argentina, Colombia, and 
Peru). National HPV vaccination programmes, targeting 
girls aged 9-11 years, were initiated in 2008 in Mexico, 
Panama, Argentina and Peru.39-43
Artículo originAl
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Table II
multiple regression analyses to identify the best demographiC, soCioeConomiC
and publiC health Correlates, in 2000-2005, of between-Country differenCes in CerviCal CanCer mortality,
in 2008, in latin ameriCa and the Caribbean islands
Correlates ß* 95% CI P R2
All LAC countries examined (n=26)
 Model with SE variables only    77%
  Estimated mortality under 5 years old (per 1 000)10 0.05 (-0.04, 0.15) 0.26 
  Per capita total expenditure on health ‡10 -0.01 (-0.10; -0.003) 0.04 
  Proportion of population with access to improved sanitation (%)11 -2.42 (-0.22, 0.01) 0.07 
Subset of LAC countries with available HPV prevalence data (n=10)
 Model with any HPV prevalence only§    8%
  Prevalence of any HPV genotype16 0.17 (-0.38, 0.72) 0.49 
 Model with high-risk HPV prevalence only §,#    9%
  Prevalence of high-risk HPV genotypes16 0.50 (-0.93, 1.93) 0.44 
 Model with SE variables only    90%
  Estimated mortality under 5 years old (per 1 000)10 0.14 (-0.005, 0.28) 0.06 
  Per capita total expenditure on health‡10 -0.004 (-0.01, 0.001) 0.10 
  Proportion of population with access to improved sanitation (%)11 -0.07 (-0.22, 0.08) 0.31 
 Model with SE variables and prevalence of any HPV genotype§    97%
  Estimated mortality under 5 years old (per 1 000)10 0.21 (0.04, 0.38) 0.03 
  Per capita total expenditure on health‡10 0.002 (-0.01, 0.003) 0.24 
  Proportion of population with access to improved sanitation (%)11 -0.01 (-0.18, 0.17) 0.93 
  Prevalence of any HPV genotype16 0.16 (0.01, 0.32) 0.04 
 Model with SE variables and prevalence of high-risk HPV genotypes§,#    98%
  Estimated mortality under 5 years old (per 1 000)10 0.15 (0.07, 0.82) 0.03 
  Per capita total expenditure on health ‡10 -0.005 (-0.01, 0.004) 0.07 
  Proportion of population with access to improved sanitation (%)11 -0.04 (-0.19, 0.11) 0.52 
  Prevalence of high-risk HPV genotypes16 0.45 (0.07, 0.82) 0.03 
HPV=Human Papillomavirus; SE=socioeconomic
* This coefficient represents the slope of the linear regression, which means the rate of change of CC mortality associated with a unit increase in the exposure 
variable
‡ At international dollar rate
§ Adjusting for age at time of HPV ascertainment
# HPV16 and HPV 18
Discussion
This ecological study found that markers of level of SE 
development were inversely associated with CC mor-
tality. Using data from 127 developing countries, Drain 
et al.44 found that country-specific CC incidence rates 
were negatively associated with health indicators but, 
in contrast to our study, CC incidence was not inversely 
associated with most SE indicators; in fact, there was a 
positive relationship between health expenditure and 
CC incidence, which was attributed to China having 
both low health spending and low CC incidence.
 Individual-based studies carried out in LAC have 
shown that CC mortality and incidence are associated 
with SE status.45 Women with a low SE status may have 
a more risky sexual behaviour, thus increasing their like-
lihood of acquiring a HPV infection, and an increased 
risk of HPV persistence and progression to pre-invasive 
lesions due, for instance, to higher smoking prevalence46 
and higher parity.47 They are also more likely to have 
poor access to health services including early detection, 
diagnostic and treatment facilities.7,48
 Improvements in the SE level of a country, even in 
the absence of a well-established screening programme, 
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may decrease CC mortality rates,49 perhaps to declines in 
HPV prevalence and increased access to early detection 
and treatment.50,51 Data from three population-based 
cancer registries in LAC (Cali in Colombia, Costa Rica 
and Ecuador) show a decline in CC incidence from 1970 
to 1995, a period when Pap smear coverage remained 
low but SE level improved.2
 In the subset of 10 countries for which HPV 
prevalence estimates were available, high-risk HPV 
prevalence alone explained only 9% of the between-
country variability in CC mortality whereas SE corre-
lates explained 90%. However, when both SE correlates 
and high-risk HPV prevalence were included in the 
same model, these variables explained practically all 
between-country variability in CC mortality (R2=98%). 
These findings suggest that SE indicators may be a better 
correlate of between-country differences in CC mortality 
than HPV prevalence; however, they may simply reflect 
the much better quality of the SE data.
 The paucity of comparable data on Pap smear 
coverage precluded examination of the extent to which 
between-country differences in CC mortality reflected 
differences in screening activity. The available estimates 
indicate that coverage is likely to have been low in most 
countries. Previous studies revealed low cytology qual-
ity, poor follow-up and poor treatment compliance.52 
A study carried out by RedPac, an initiative set up to 
monitor and improve Pap smear quality in LAC, showed 
that cytology quality was poor in many countries (e.g. 
percentage of false-negatives in 2000 was 27% in Peru, 
23% in Venezuela, and <5% in Chile and Costa Rica).18,35 
The effectiveness of screening was also affected by poor 
turnaround time,53 mainly in rural areas,54 with only 
34% abnormal smears being appropriately followed-up 
in Peru, 59% in Bolivia, and >90% in Chile and Cuba.18 
New screening methods (e.g. visual inspection after 
acetic acid [VIA] and HPV testing) are being adopted in 
certain LAC countries (table IV) but their introduction 
is far too recent to have had any major impact on the 
mortality rates examined here.
 Our study is not exempt of limitations. Firstly, the 
analyses relied on mortality data, which reflects both 
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figure 1. Correlation between the Composite risk sCore (see methods and results seCtions), 2000-2005, and age-
adjusted CC mortality rates, in 2008, in latin ameriCa and the Caribbean islands (laC): (a) all 26 laC Countries 
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observed CC rates and the line to those prediCted by the linear regression model)
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Table III
the best identified demographiC, soCioeConomiC and publiC health Correlates (and Corresponding Composite 
sCores*), in 2000-2005, of between-Country differenCes in CerviCal CanCer mortality, in 2008,
in latin ameriCa and the Caribbean islands
   Country Adjusted CC Estimated mortality under Per capita total expenditure on Proportion of population
 (composite risk score) Mortality rate 5 years old (per 1 000)10 health at international with access to improved
    dollar rate10 sanitation (%)11
CC mortality less than 10 per 100 000 women year
  Chile (15) 6.6 9.3     707 92
 Costa Rica (17) 6.7 11.9     616 92
 Uruguay (14) 6.8 14.8     824 94
 Argentina (19) 7.4 16.7 1 067 82
 Cuba (23) 8.9 7.1      251 98
 Bahamas (8) 9.5 15.3 1 220 100
 Mexico (31) 9.7 22.9     582 77
 Barbados (9) 9.9 11.6 1 050 99
 Mean (SD) 8.2 (1.5) 13.7 (4.9) 789.6 (316.5) 91.8 (8.3)
CC mortality 10 to 16 per 100 000 women year
 Colombia (35) 10.0 30.9 522 86
 Brazil (38) 10.9 33.3 597 75
 Suriname (34) 11.1 29.4 309 93
 Trinidad and Tobago (19) 11.5 18.6 532 100
 Panama (35) 12.6 25.7 555 72
 Ecuador (51) 13.3 28.2 220 72
 Dominican Republic (59) 13.7 47.7 335 57
 Venezuela (51) 14.4 28.0 231 68
 Guatemala (65) 15.2 48.1 235 61
 Belize (59) 15.3 40.2 309 47
  Mean (SD) 12.8 (1.9) 33.0 (9.6) 384.5 (149.7) 73.1 (10.9)
CC mortality more than 16 per 100 000 women year
 Peru (66) 16.3 49.5 233 62
 Paraguay (48) 16.6 43.6 301 78
 Bolivia (78) 16.7 67.6 176 45
 El Salvador (49) 18.2 32.5 378 63
 Honduras (65) 19.7 46.3 184 68
 Jamaica (43) 20.3 20.3 216 80
 Guyana (59) 20.5 64.6 283 70
 Nicaragua (62) 20.6 38.0 208 66
  Mean (SD) 18.6 (1.9) 45.3 (15.7) 247.4 (68.7) 66.5 (10.9)
* country-specific score estimated as the sum of the ranking of the three predictors identified by the multiple regression  analysis with a possible range from 
3 to 78 (see Methods and Results sections)
incidence of, and survival from, CC. There are few 
population-based cancer registries in LAC and most are 
local. The quality of the mortality data was also far from 
ideal. The estimates produced by GLOBOCAN (IARC/
WHO) took into account under-registration of death and 
percentage of registered deaths coded as “ill-defined” 
conditions, but different methods were used to estimate 
rates for each country depending on data availability. 
Secondly, the SE data came from different sources al-
though for every single variable the same source was 
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Table IV
CerviCal sCreening and hpv vaCCination poliCies in latin ameriCa and the Caribbean islands (laC), 2011*
 Coverage Estimates 
Country Start year‡ Screening Screening Screening Screening No. of women Age Interval % of women HPV vaccination 
  centres age (years) scheme test studied   screened policies 
    (years)§  (year)   (reference)
Argentina 1997 Health care centres 35-64  1-1-3 Pap, HPV test 41 392 (2005) >18 2/Ever 51.6/74.424 All girls from 11 years from 201142
     (pilot study) 
Bolivia  1988 and 1998 Reproductive health service 25-49  1-1-3 Pap -- -- -- -- --
Brazil 1968/1996-98 Health facilities 25-59  1-1-3 Pap NS (2003) > 24 3 68.720 Not universal, study assessing
          cost-effectiveness in Brasil40
Chile  1987 and 1994 Health primary clinics 25-64 Every 3 Pap 270 000 (2003) > 15 3 51.431 Not universal
Colombia# 1991 and 2000 NS 25-69   1-1-3 Pap 41 012 (2005) 18-69 2 6727 --
Costa Rica 1995 Health public and private > 20 Every 2 Pap 1612 (1999-2000) 18-44 2/Ever 44.8/78.825 --
  centres 
Cuba# 1968 Health primary clinics 25-59 Every 3 Pap NS (1993-1994) <20 2 54.226 --
Dominican
Republic#  1993 Family planning services 25-59 6-6-12 (months) 4 996 (1996) NS 1 44.835 --
Ecuador& 1996 Health primary service 35-64 Every 5 Pap 10 813 (2004) 15-49 2 3128 --
El Salvador  2002 Family planning services 30-59 Every 2 Pap 10 689 (2002-2003) 15-49 Ever 84.733 --
Guatemala 2004 Familyplanningservices 25-49 1-1-1-3
    or 5 Pap 12 119 (2002) 15-49 1 41.236 --
Honduras  NS Maternal health 25-59 Annually Pap 9 362 (2001) 15-49 Ever 60.933 --
Mexico 1974/1994-98 Public health sector 25 -64  1-1-3 PAP, VIA and 4 594 672 (2000) >25 3 57.8(f)30 About to start national vaccination
     HPV test     programme of 9-11 years old (2009)39 
Nicaragua  2003 Women’s health clinics 25-59 1-1-1-3 Pap 14 671 (2001) 14-49 1 23.338 --
Panama NS NS 25-years Every 3 Pap -- -- -- -- Originally >10 years, entire country
          since 2008, program under evaluation43
Paraguay  2002≠ Health care centres 25-69 1-1-1-3 Pap 7 321 (2004) 15-44 2/Ever 50.9/69.629 --
  and hospitals 
Peru  2000 and 2004 Primary care health service 30-49 Every 3 PAP, VIA NS(1998) 15-49 1 22.737 260 thousands girls 11 years to be
     and HPV test     vaccinated since 201141
Trinidad &
Tobago# Development NS 20-59  1-1-3 Pap 903 (1987) NS Ever 35.435 --
Uruguay Have not issued any cervical cancer screening guidelines. Pap - (NS) 20-59 Ever7034 --
 Opportunistic screening is offered by some clinics since 1994  
Venezuela 1996 NS 25-64 Every 3 Pap -- -- -- -- --
NS: Not specified         
* Updated (to the end of 2011) and modified from Murillo et al 200818 
‡ Second date is the year of re-launch of the programme
§ Screening schemes in the format “1-1-3” mean annual screening until 2 consecutive negative smears and every 3 years afterwards
# Source: unpublished data, based on personal reports
& Started in Quito and the Manabi province and was used as a reference for the whole country
≠	 Start of programme implementation
∞	 Estimated by data from the Screening Programm
used for all 26 countries examined; reassuringly, the SE 
correlations with CC mortality were rather consistent 
despite the different quality of the data on the vari-
ous SE indicators. Thirdly, HPV prevalence estimates, 
available for only 10 countries, were derived from local 
surveys using HCII or PCR methodology. The extent 
to which such surveys were nationally representative 
is unknown. Fourthly, data on screening activity and 
quality were scarce; national estimates of Pap-smear 
coverage were available only for a few countries based 
on different (non-comparable) methodologies. Finally, 
the findings relate to countries and cannot be extrapo-
lated to an individual level.
 In summary, CC mortality remains high in LAC. 
Our findings imply that improvements in the level of 
SE development of a country may reduce CC mortality 
even in the absence of organised screening programmes 
and HPV vaccination programmes. 
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